Catalyst Retained Earnings from 2010 to 2024

CPRX Stock

USD 22.07 0.27 1.21%

Catalyst Pharmaceuticals Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Catalyst Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2004-12-31

Previous Quarter

185.3 M

Current Value

229.2 M

Quarterly Volatility

74.6 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 327 M or Operating Income of 91.2 M, as well as many indicators such as Price To Sales Ratio of 4.26, Dividend Yield of 0.0 or PTB Ratio of 4.38. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.

For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Latest Catalyst Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Catalyst Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Catalyst Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 121.27 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Catalyst Retained Earnings Regression Statistics

	Arithmetic Mean	(40,084,334)
	Geometric Mean	56,805,794
	Coefficient Of Variation	(213.06)
	Mean Deviation	63,111,814
	Median	(53,705,624)
	Standard Deviation	85,404,042
	Sample Variance	7293.9T
	Range	287.9M
	R-Value	0.44
	Mean Square Error	6341.3T
	R-Squared	0.19
	Significance	0.10
	Slope	8,382,986
	Total Sum of Squares	102113.9T

Catalyst Retained Earnings History

	2024	127.3 M
	2023	121.3 M
	2022	49.9 M
	2021	-26.3 M
	2020	-53.7 M
	2019	-128.7 M
	2018	-160.6 M

Other Fundumenentals of Catalyst Pharmaceuticals

Retained Earnings Total Equity

Catalyst Pharmaceuticals Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Total Liab	Total Current Assets	Retained Earnings	Accounts Payable	Common Stock	Property Plant Equipment	Net Receivables	Net Tangible Assets	Short Term Investments	Capital Surpluse	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock	Current Deferred Revenue	Short Term Debt
Total Assets		1.0	-0.8	0.98	0.91	0.79	0.9	0.48	0.47	0.83	0.99	-0.5	0.68	0.89	0.75	0.51	0.81	-0.87	0.1
Total Stockholder Equity	1.0		-0.79	0.97	0.91	0.79	0.9	0.5	0.48	0.83	0.99	-0.49	0.69	0.89	0.75	0.51	0.81	-0.86	0.08
Net Debt	-0.8	-0.79		-0.79	-0.97	-0.52	-0.47	-0.61	-0.54	-0.35	-0.84	0.44	-0.74	-0.8	-0.95	0.09	-0.41	0.64	0.03
Total Liab	0.98	0.97	-0.79		0.9	0.81	0.88	0.42	0.39	0.82	0.96	-0.56	0.63	0.89	0.75	0.5	0.81	-0.92	0.18
Total Current Assets	0.91	0.91	-0.97	0.9		0.61	0.66	0.64	0.56	0.56	0.95	-0.41	0.79	0.86	0.91	0.13	0.58	-0.74	0.01
Retained Earnings	0.79	0.79	-0.52	0.81	0.61		0.75	-0.1	0.3	0.7	0.74	-0.72	0.15	0.79	0.63	0.62	0.75	-0.82	0.19
Accounts Payable	0.9	0.9	-0.47	0.88	0.66	0.75		0.33	0.25	0.97	0.85	-0.45	0.53	0.73	0.4	0.77	0.89	-0.81	0.11
Common Stock	0.48	0.5	-0.61	0.42	0.64	-0.1	0.33		0.37	0.28	0.55	0.23	0.95	0.45	0.4	-0.14	0.09	-0.23	-0.12
Property Plant Equipment	0.47	0.48	-0.54	0.39	0.56	0.3	0.25	0.37		0.2	0.53	-0.05	0.45	0.47	0.57	-0.06	0.19	-0.07	0.17
Net Receivables	0.83	0.83	-0.35	0.82	0.56	0.7	0.97	0.28	0.2		0.77	-0.37	0.46	0.65	0.29	0.86	0.87	-0.8	0.24
Net Tangible Assets	0.99	0.99	-0.84	0.96	0.95	0.74	0.85	0.55	0.53	0.77		-0.46	0.74	0.89	0.79	0.41	0.76	-0.81	0.03
Short Term Investments	-0.5	-0.49	0.44	-0.56	-0.41	-0.72	-0.45	0.23	-0.05	-0.37	-0.46		-0.03	-0.54	-0.49	-0.23	-0.48	0.57	-0.01
Capital Surpluse	0.68	0.69	-0.74	0.63	0.79	0.15	0.53	0.95	0.45	0.46	0.74	-0.03		0.66	0.54	0.02	0.27	-0.44	-0.08
Net Invested Capital	0.89	0.89	-0.8	0.89	0.86	0.79	0.73	0.45	0.47	0.65	0.89	-0.54	0.66		0.8	0.36	0.52	-0.8	0.14
Net Working Capital	0.75	0.75	-0.95	0.75	0.91	0.63	0.4	0.4	0.57	0.29	0.79	-0.49	0.54	0.8		-0.08	0.39	-0.63	0.02
Long Term Investments	0.51	0.51	0.09	0.5	0.13	0.62	0.77	-0.14	-0.06	0.86	0.41	-0.23	0.02	0.36	-0.08		0.73	-0.61	0.35
Capital Stock	0.81	0.81	-0.41	0.81	0.58	0.75	0.89	0.09	0.19	0.87	0.76	-0.48	0.27	0.52	0.39	0.73		-0.78	0.08
Current Deferred Revenue	-0.87	-0.86	0.64	-0.92	-0.74	-0.82	-0.81	-0.23	-0.07	-0.8	-0.81	0.57	-0.44	-0.8	-0.63	-0.61	-0.78		-0.25
Short Term Debt	0.1	0.08	0.03	0.18	0.01	0.19	0.11	-0.12	0.17	0.24	0.03	-0.01	-0.08	0.14	0.02	0.35	0.08	-0.25

Click cells to compare fundamentals

About Catalyst Pharmaceuticals Financial Statements

Catalyst Pharmaceuticals investors use historical fundamental indicators, such as Catalyst Pharmaceuticals' Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	121.3 M	127.3 M
Retained Earnings Total Equity	57.3 M	60.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC